Brought to you by 
Biodesix to market VeriStrat companion test for Aveo’s ficlatuzumab
09 Sep 2020
Executive Summary
Biodesix Inc. (multivariate testing in oncology) agreed to market its VeriStrat as a companion diagnostic to cancer company Aveo Pharmaceuticals Inc.’s ficlatuzumab, an anti-hepatocyte growth factor antibody in Phase II for non-small cell lung cancer (NSCLC). VeriStrat is a serum proteomic blood test that stratifies NSCLC patients based on the expected outcome with EGFR tyrosine kinase inhibitor treatment.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biodesix to market VeriStrat companion test for Aveo’s ficlatuzumab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice